Please assess the completion status of the following clinical trial:

Trial Title: Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Liver biopsy consistent with NASH cirrhosis.~2. Compensated cirrhosis due to NASH.~Key Exclusion Criteria:~1. Other causes of liver disease including but not limited to alcoholic liver disease, hepatitis B, hepatitis C, autoimmune disorders, primary biliary cirrhosis, drug-induced hepatotoxicity, Wilson's disease, hemochromatosis, and alpha-1-anti-trypsin definition based on medical history and/or centralized read of liver histology.~2. Evidence of drug induced steatohepatitis secondary to amiodarone, corticosteroids, estrogens, methotrexate, tetracycline, or other medications known to cause hepatic steatosis.~3. History of hepatic decompensation including variceal bleeding, ascites, or hepatic encephalopathy.~4. Model of end stage liver disease (MELD) score \>12.~Other protocol-defined inclusion/exclusion criteria could apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Daily 0.3 mg dose (Type: EXPERIMENTAL): Administered by subcutaneous injection
- Daily 1 mg dose (Type: EXPERIMENTAL): Administered by subcutaneous injection
- Daily 3 mg dose (Type: EXPERIMENTAL): Administered by subcutaneous injection
- Placebo (Type: PLACEBO_COMPARATOR): Administered by subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).